UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 10-Q

(Mark One)

     [X]      QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
              SECURITIES EXCHANGE ACT OF 1934

              For the quarterly period ended November 30, 1999.

 OR

     [ ]      TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
              SECURITIES EXCHANGE ACT OF 1934

              For the transition period from _______________ to _______________.

Commission file Number 0-12515.

BIOMET, INC.
(Exact name of registrant as specified in its charter)

Indiana                                                      35-1418342
(State or other jurisdiction of                              (I.R.S. Employer
incorporation or organization)                               Identification No.)

Airport Industrial Park, P.O. Box 587, Warsaw, Indiana  46581-0587
(Address of principal executive offices)

(219) 267-6639
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.  Yes  X    No

As of November 30, 1999, the registrant had 112,857,994 common shares
outstanding.


BIOMET, INC.

CONTENTS

                                              										                 Pages

    Part I.  Financial Information

      Item 1.  Financial Statements:

                 Consolidated Balance Sheets                               1-2

                 Consolidated Statements of Income                           3

                 Consolidated Statements of Cash Flows                       4

                 Notes to Consolidated Financial Statements                5-9

      Item 2.  Management's Discussion and Analysis of
               Financial Condition and Results of Operations             10-12


    Part II.   Other Information                                            13

    Signatures                                                              14

    Index to Exhibits                                                       15



PART I.  FINANCIAL INFORMATION

ITEM 1.  FINANCIAL STATEMENTS

BIOMET, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS
at November 30, 1999 and May 31, 1999
(in thousands)

ASSETS
                                                November 30,        May 31,
                                                    1999              1999
                                                ------------        -------
Current assets:
  Cash and cash equivalents                     $  164,257       $  129,359
  Investments                                       84,500           60,078
  Accounts and notes receivable, net               226,879          215,034
  Refundable income taxes                           31,308           31,308
  Inventories                                      227,544          205,238
  Prepaid expenses and other                        45,637           40,691
                                                 ---------        ---------
      Total current assets                         780,125          681,708
                                                 ---------        ---------
Property, plant and equipment, at cost             285,487          265,010
    Less, Accumulated depreciation                 108,961           96,137
                                                 ---------        ---------
      Property, plant and equipment, net           176,526          168,873
                                                 ---------        ---------
Investments                                        125,840          146,859
Intangible assets, net                               8,523            7,665
Excess acquisition costs over fair value
  of acquired net assets, net                       54,746           47,861
Other assets                                        15,751           14,990
                                                 ---------        ---------
Total assets                                    $1,161,511       $1,067,956
                                                 =========        =========

The accompanying notes are a part of the consolidated financial statements.

BIOMET, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS
at November 30, 1999 and May 31, 1999
(in thousands)

LIABILITIES AND SHAREHOLDERS' EQUITY
                                                 November 30,        May 31,
                                                    1999              1999
                                                 ------------        -------
Current liabilities:
  Short-term borrowings                          $   70,099       $   45,137
  Accounts payable                                   28,856           27,676
  Accrued income taxes                                9,565           17,088
  Accrued wages and commissions                      18,763           19,596
  Other accrued liabilities                         107,094           91,933
                                                  ---------        ---------
     Total current liabilities                      234,377          201,430

Long-term liabilities:
  Deferred federal income taxes                       8,414            9,565
  Other liabilities                                     447              324
                                                  ---------        ---------
     Total liabilities                              243,238          211,319
                                                  ---------        ---------
Minority interest                                    83,951           80,690
                                                  ---------        ---------
Contingencies (Note 8)

Shareholders' equity:
  Common shares                                      80,288           77,843
  Additional paid-in capital                         26,920           26,920
  Retained earnings                                 747,489          687,828
  Accumulated other comprehensive income            (20,375)         (16,644)
                                                  ---------        ---------
     Total shareholders' equity                     834,322          775,947
                                                  ---------        ---------
Total liabilities and shareholders' equity       $1,161,511       $1,067,956
                                                  =========        =========

The accompanying notes are a part of the consolidated financial statements.

BIOMET, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME
for the six and three month periods ended November 30, 1999 and 1998
(in thousands, except per share data)

                                    Six Months Ended      Three Months Ended
                                       November 30,           November 30,
                                    ----------------       ------------------
                                    1999        1998        1999        1998
                                    ----        ----        ----        ----

Net sales                         $394,631    $360,004    $202,480    $183,340

Cost of sales                      117,527     109,102      60,691      55,585
                                   -------     -------     -------     -------
  Gross profit                     277,104     250,902     141,789     127,755

Selling, general and
  administrative expenses          135,490     123,979      69,194      63,100
Research and development expense    16,842      17,254       8,304       9,162
Special charge                       9,000          --       9,000          --
                                   -------     -------     -------     -------
  Operating income                 115,772     109,669      55,291      55,493

Other income, net                    7,983       7,419       4,864       4,575
                                   -------     -------     -------     -------
  Income before income taxes
    and minority interest          123,755     117,088      60,155      60,068

Provision for income taxes          45,047      43,214      22,167      22,118
                                   -------     -------     -------     -------
  Income before minority interest   78,708      73,874      37,988      37,950

Minority interest                    3,261       4,386       1,845       2,056
                                   -------     -------     -------     -------
  Net income                      $ 75,447    $ 69,488    $ 36,143    $ 35,894
                                   =======     =======     =======     =======
Earnings per share:
  Basic                               $.67        $.62        $.32        $.32
                                      ====        ====        ====        ====
  Diluted                             $.66        $.61        $.32        $.32
                                      ====        ====        ====        ====
Shares used in the computation
  of earnings per share:
  Basic                            112,839     112,184     112,774     112,258
                                   =======     =======     =======     =======
  Diluted                          113,723     113,564     114,004     113,651
                                   =======     =======     =======     =======
Cash dividends per common share       $.14        $.12        $ --        $ --
                                      ====        ====        ====        ====

The accompanying notes are a part of the consolidated financial statements.

BIOMET, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
for the six months ended November 30, 1999 and 1998
(in thousands)

                                                          1999          1998
                                                          ----          ----
Cash flows from (used in) operating activities:
  Net income                                            $ 75,447      $ 69,488
  Adjustments to reconcile net income to
    net cash from operating activities:
      Depreciation                                        12,083         9,531
      Amortization                                         4,036         4,161
      Gain on sale of investments, net                      (432)       (1,054)
      Minority interest                                    3,261         4,386
      Deferred federal income taxes                         (181)         (242)
      Changes in current assets and liabilities,
       excluding effects of acquisitions:
        Accounts and notes receivable, net               (10,041)      (12,842)
        Inventories                                      (18,167)      (13,735)
        Prepaid expenses and other                        (2,652)        7,444
        Accounts payable                                     (73)       (1,404)
        Accrued income taxes                              (8,026)        9,921
        Accrued wages and commissions                       (639)         (507)
        Other accrued laibilities                         12,577        (4,764)
                                                         -------        ------
        Net cash from operating activities                67,193        70,383
                                                         -------        ------
Cash flows from (used in) investing activities:
  Proceeds from sales and maturities of investments        7,323        24,171
  Purchases of investments                               (13,288)      (62,648)
  Capital expenditures                                   (20,881)      (19,374)
  Acquisitions, net of cash acquired                     (13,530)       (1,075)
  Other                                                   (1,720)       (1,963)
                                                         -------        ------
        Net cash used in investing activities            (42,096)      (60,889)
                                                         -------        ------
Cash flows from (used in) financing activities:
  Increase in short-term borrowings, net                  24,435         2,166
  Issuance of common shares                                2,439           982
  Cash dividends                                         (15,786)      (13,453)
                                                         -------        ------
        Net cash from (used in) financing activities      11,088       (10,305)
                                                         -------        ------
Effect of exchange rate changes on cash                   (1,287)       (1,289)
                                                         -------        ------
Increase (decrease) in cash and cash equivalents          34,898        (2,100)
Cash and cash equivalents, beginning of year             129,359       117,089
                                                         -------       -------
Cash and cash equivalents, end of period                $164,257      $114,989
                                                         =======       =======

The accompanying notes are a part of the consolidated financial statements.

BIOMET, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1:     BASIS OF PRESENTATION.

The accompanying consolidated financial statements include the accounts of
Biomet, Inc. and its subsidiaries (individually and collectively referred to as
the "Company").  The unaudited consolidated financial statements have been
prepared in accordance with generally accepted accounting principles for
interim financial information and with the instructions to Form 10-Q and Rule
10-01 of Regulation S-X.  Accordingly, they do not include all of the
information and notes required by generally accepted accounting principles for
complete financial statements.  In the opinion of management, all adjustments
(consisting of normal recurring accruals) considered necessary for a fair
presentation have been included.  Operating results for the six-month period
ended November 30, 1999 are not necessarily indicative of the results that may
be expected for the fiscal year ending May 31, 2000.  For further information,
refer to the consolidated financial statements and notes thereto included in
the Company's Annual Report on Form 10-K for the fiscal year ended May 31, 1999.

The accompanying consolidated balance sheet at May 31, 1999, has been derived
from the audited Consolidated Financial Statements at that date, but does not
include all disclosures required by generally accepted accounting principles.

The Company has one reportable segment, orthopedic products, which includes
designing, manufacturing and marketing of reconstructive products, fixation
devices, spinal products and other.  Other products consist primarily of
Arthrotek's arthroscopy products, AOA's softgoods products, general instruments
and operating room supplies.  The Company manages its business segments
primarily on a geographic basis.  These geographic segments are comprised of
the United States, Europe and other.  Other geographic segments include Canada,
South America, Mexico, Japan, and the Pacific Rim.

Net sales of orthopedic products by product category are as follows for the
six and three months ended November 30:

                                Six Months Ended          Three Months Ended
                                  November 30,               November 30,
                                ----------------          ------------------
                                1999        1998           1999        1998
                                ----        ----           ----        ----
                                               (in thousands)

     Reconstructive           $233,085    $213,376       $120,565    $109,628
     Fixation                   85,363      78,341         43,329      38,899
     Spinal products            25,119      20,819         12,951      11,062
     Other                      51,064      47,468         25,635      23,751
                               -------     -------        -------     -------
                              $394,631    $360,004       $202,480    $183,340
                               =======     =======        =======     =======

NOTE 2:     COMPREHENSIVE INCOME.

Other comprehensive income includes foreign currency translation adjustments
and unrealized appreciation of available-for-sale securities, net of taxes.
Other comprehensive income (loss) for the three months ended November 30, 1999
and 1998 was $(977) and $9,000, respectively.  Other comprehensive income (loss)
for the six months ended November 30, 1999 and 1998 was ($3,731) and $8,713,
respectively.  Total comprehensive income combines reported net income and other
comprehensive income.  Total comprehensive income for the three months ended
November 30, 1999 and 1998 was $35,166 and $44,894, respectively. Total
comprehensive income for the six months ended November 30, 1999 and 1998 was
$71,716 and $78,201, respectively.

NOTE 3:     INVENTORIES.

Inventories at November 30, 1999 and May 31, 1999 are as  follows:

                               November 30,      May 31,
                                   1999           1999
                               ------------      -------
                                     (in thousands)

        Raw materials            $ 28,218       $ 26,372
        Work-in-process            26,214         24,221
        Finished goods             93,446         87,362
        Consigned inventory        79,666         67,283
                                  -------        -------
                                 $227,544       $205,238
                                  =======        =======

NOTE 4:     COMMON SHARES.

During the six months ended November 30, 1999, the Company issued 280,490 Common
Shares upon the exercise of outstanding stock options for proceeds aggregating
$2,438,976.

NOTE 5:     EARNINGS PER SHARE.

Earnings per common share amounts ("basic EPS") are computed by dividing net
income by the weighted average number of common shares outstanding and excludes
any potential dilution.  Earnings per common share amounts assuming dilution
("diluted EPS") are computed by reflecting potential dilution from the
exercise of stock options.

NOTE 6:     INCOME TAXES.

The difference between the reported provision for income taxes and a provision
computed by applying the federal statutory rate to pre-tax accounting income is
primarily attributable to state income taxes, tax benefits relating to
operations in Puerto Rico, tax-exempt income and tax credits.

NOTE 7:     SUBSEQUENT EVENT.

On December 16, 1999, the Company and Implant Innovations International
Corporation ("3i") completed the merger as previously announced.  The Company
issued 5.2 million Common Shares for all of the issued and outstanding shares of
3i.  3i and its subsidiaries design, develop, manufacture, market and distribute
oral reconstructive products.  3i's corporate headquarters and manufacturing
facility are located in Palm Beach, Florida and it has sales offices in Canada,
Europe and Mexico.  The business combination will be accounted for as a
pooling-of-interests whereby all prior period financial statements of the
Company will be restated to include the combined financial position, results
of operations and cash flows of the Company and 3i.  The following supplementary
pro forma financial information combines 3i's operating results with the
Company's for the periods presented.  The supplementary pro forma financial
information is subject to final adjustments and revisions; however, management
believes adjustments, if any, will not be material.  Further, management does
not expect there will be any material adjustments to conform the accounting
policies of the two companies.  The Company will take a one-time pretax charge
of approximately $2.7 million for merger-related costs during the third quarter
of fiscal year 2000.

             Supplementary Pro Forma Financial Information

                                Six Months Ended          Three Months Ended
                                  November 30,               November 30,
                                ----------------          ------------------
                                1999        1998           1999        1998
                                ----        ----           ----        ----
                                   (in thousands, except per share data)

     Reconstructive           $275,910    $247,740       $142,832    $127,747
     Fixation                   85,363      78,341         43,329      38,899
     Spinal products            25,119      20,819         12,951      11,062
     Other                      51,064      47,468         25,635      23,751
                               -------     -------        -------     -------
                              $437,456    $394,368       $224,747    $201,459
                               =======     =======        =======     =======
     U.S. sales               $293,116    $263,538       $149,926    $134,894
     Foreign sales             144,340     130,830         74,821      66,565
                               -------     -------        -------     -------
                              $437,456    $394,368       $224,747    $201,459
                               =======     =======        =======     =======
     Net sales                $437,456    $394,368       $224,747    $201,459
     Gross profit              304,592     269,578        156,349     137,693
     Operating income          124,003     113,462         60,008      57,793
     Net income                 79,958      71,541         38,186      37,150
     Basic earnings per share      .68         .62            .33         .32
     Diluted earning per share     .67         .60            .33         .31

                                                         Three Months Ended
                                                February 28, 1999   May 31, 1999
                                                -----------------   ------------
                                           (in thousands, except per share data)

          Reconstructive                               $131,757        $141,868
          Fixation                                       41,191          43,293
          Spinal products                                11,642          12,664
          Other                                          25,101          26,018
                                                        -------         -------
                                                       $209,691        $223,843
                                                        =======         =======
          U.S. sales                                   $139,489        $145,485
          Foreign sales                                  70,202          78,358
                                                        -------         -------
                                                       $209,691        $223,843
                                                        =======         =======
          Net sales                                    $209,691        $223,843
          Gross profit                                  143,552         155,346
          Operating income, excluding special items (a)  58,567          62,329
          Income, excluding special items (b)            38,342          43,914
          Income per share, excluding special items (b):
          Basic                                             .33             .38
          Diluted                                           .32             .37

     (a)  Operating income, excluding special items for the three month period
          ended May 31, 1999 excludes a $55 million special charge for
          litigation for Biomet and $6.6 million of special income from a
          litigation settlement of 3i.
     (b)  Income, excluding special items for the three month period ended May
          31, 1999 excludes a $32.9 million special charge (net of tax) for
          litigation for Biomet and $4.1 million of special income (net of tax)
          from a litigation settlement of 3i.  Income per share excludes the
          per share effect of the above noted special items - $.25 (basic) and
          $.24 (diluted).

NOTE 8:      CONTINGENCIES.

On June 30, 1999, the United States Court of Appeals for the Third Circuit (the
"Third Circuit") significantly reduced the judgment previously entered against
the Company and its wholly-owned subsidiaries, Electro-Biology, Inc. and EBI
Medical Systems, Inc. and in favor of Orthofix SRL ("Orthofix").  The Third
Circuit upheld the trial court's award of compensatory damages to Orthofix in
the amount of $48,875,397; however, it virtually eliminated the $50 million
punitive damage award, reducing it to $1 million.  The Company and Orthofix
filed petitions for rehearing with the Third Circuit and both petitions were
denied.  Orthofix filed an appeal of the Third Circuit's decision to the United
States Supreme Court, and on January 10, 2000 the Supreme Court decided, without
comment, not to review the decision of the lower court.  As a result of the
Third Circuit's decision, and consultation with outside legal counsel, the
Company recorded a special charge of $55 million in its fiscal 1999 consolidated
financial statements.  The Company recorded an additional special charge of $9
million for the quarter ended November 30, 1999 to reflect the final
determination of the interest element of the judgment.  On November 30, 1999,
the Company's investments on the consolidated balance sheet include $108 million
of investment securities which were previously delivered to an escrow agent
pursuant to an order of the trial court.  It is anticipated that the final
amount payable to Orthofix of approximately $64 million will be paid prior to
January 31, 2000, at which time this matter will be finally resolved and the
escrow account closed.

ITEM 2.      MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
             CONDITION AND RESULTS OF OPERATIONS

FINANCIAL CONDITION AS OF NOVEMBER 30, 1999

The Company's cash and investments increased $38,301,000 from $336.3 million at
May 31, 1999 to $374.6 million at November 30, 1999, net of the $15,786,000 cash
dividend paid during the first quarter.

Cash flows provided by operating activities were $67,193,000 for the first six
months of fiscal 2000 compared to $70,383,000 in 1999.  Net income plus
depreciation and amortization and the increase in other liabilities were the
principal sources of cash from operating activities, offset by increases in
accounts receivable, inventories and accrued income taxes.

Cash flows used in investing activities were $42,096,000 for the first six
months of fiscal 2000 compared to a use of $60,889,000 in 1999.  The primary
source of cash flows from investing activities were sales and maturities of
investments offset by purchases of investments, purchases of capital equipment
and business acquisitions.

Cash flows from financing activities were $11,088,000 for the first six months
of fiscal 2000 compared to a use of $10,305,000 in 1999.  The primary use of
cash flows from financing activities was the cash dividend paid in the first
quarter while the primary source of cash flows from financing activities was
from increasing short-term borrowings used by BioMer in its operations and for
business acquisitions.

Currently available funds, together with anticipated cash flows generated from
future operations, are believed to be adequate to cover the Company's
anticipated cash requirements, including capital expenditures, research and
development costs and the Orthofix judgment.

RESULTS OF OPERATIONS FOR THE SIX MONTHS ENDED NOVEMBER 30, 1999
AS COMPARED TO THE SIX MONTHS ENDED NOVEMBER 30, 1998

Net sales increased 10% to $394,631,000 for the six-month period ended November
30, 1999, from $360,004,000 for the same period last year.   The Company's
U.S.-based revenue increased 10% to $270,411,000 during the first six months,
while foreign sales increased 8% to $124,220,000, net of a negative foreign
exchange adjustment of approximately $5,000,000.  Biomet's worldwide sales of
reconstructive products during the first six months of fiscal 2000 were
$233,085,000, representing a 9% increase compared to the first six months of
last year.  This increase  was primarily a result of Biomet's continued
penetration of the reconstructive device market led by revision products, the
Repicci Unicondylar Knee and the Ascent Total Knee System.  Sales of fixation
products were $85,363,000 for the first six months of fiscal 2000, representing
a 9% increase as compared to the same period in 1999.  Sales of spinal products
were $25,119,000 for the first six months of fiscal 2000, representing a 21%
increase as compared to the same period in 1999.  Sales of spinal hardware
contributed to this increase.  The Company's sales of other products totaled
$51,064,000, representing an 8% increase over the first six months of fiscal
year 1999, primarily as a result of increased sales of softgood and Arthroscopy
products.

Cost of sales decreased as a percentage of net sales to 29.8% for the first six
months of fiscal 2000 from 30.3% last year primarily as a result of increased
sales of higher margin products, increased in-house manufacturing efficiencies,
improved margins realized through acquisitions of international distributors and
the higher growth rate of U.S. sales compared to international sales.   Selling,
general and administrative expenses as a percentage of net sales decreased
slightly from 34.4% for the first six months of last year to 34.3% for the
current six month period.  Research and development expenditures decreased
during the first six months to $16,842,000.  On January 10, 2000, the United
States Supreme Court declined to review the Third Circuit's decision in the
Orthofix case, leaving its damage award standing. The Company recorded a $9
million special charge in the second quarter of fiscal year 2000, to reflect the
final determination of the interest element of the judgment.  Operating income
rose 6% from $109,669,000 for the first six months of fiscal 1999, to
$115,772,000 for the first six months of fiscal 2000.  Excluding this special
charge, operating income would have increased 14% to $124,772,000 for the first
six months of fiscal 2000. Other income increased 8% resulting from the
increase in the Company's investable cash.  The effective income tax rate
decreased to 36.4% for the six months of fiscal year 2000 from 36.9% last year
primarily as a result of U.S. pretax income growing at a higher rate than
international pretax income where tax rates are higher.

These factors resulted in a 9% increase in net income to $75,447,000 from
$69,488,000 for the first six months of fiscal 2000 as compared to the same
period in fiscal 1999.  Basic and diluted earnings per share both increased 8%,
from $.62 and $.61 to $.67 and $.66, respectively, for the periods presented.
Excluding the effect of the special charge, net income would have increased 17%
to $81,147,000 and basic and diluted earnings per share would have both
increased 16% to $.72 and $.71, respectively.

RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED NOVEMBER 30, 1999
AS COMPARED TO THE THREE MONTHS ENDED NOVEMBER 30, 1998

Net sales increased 10% to $202,480,000 for the second quarter of fiscal year
2000, as compared to $183,340,000 for the same period last year.  Operating
income decreased .4% from $55,493,000 for the second quarter of fiscal 1999, to
$55,291,000 for the second quarter of fiscal 2000.  Excluding the special
charge, operating income would have increased 16% to $64,291,000 for the second
quarter of fiscal 2000. During the second quarter, net income increased 1% to
$36,143,000 as compared to $35,894,000 for the same period last year.  Basic and
diluted earnings per share both remained at $.32 per share for the second
quarter of fiscal 1999 and 2000.  Excluding the special charge, second quarter
net income would have increased 17% to $41,843,000 and basic and diluted
earnings per share both would have increased 16% to $.37 per share. The business
factors resulting in these changes and relevant trends affecting the Company's
business during the periods in question are comparable to those described in the
preceding discussion for the six-month period.

YEAR 2000

The Year 2000 ("Y2K") issue stems from the way dates are recorded in many
computer-dependent products and software programs.  As the century date change
occurs, date-sensitive systems may recognize the year 2000 as the year 1900, or
not at all.  This inability to recognize or properly treat the year 2000 may
cause systems to process financial or operations information incorrectly.  Prior
to January 1, 2000, the Company, its vendors and customers and other parties
made significant efforts and expenditures to upgrade, change and modify
computer-dependent products and software programs to be Y2K compliant. As a
result, the Company experienced only a few minor Y2K related problems
(subsequent to December 31, 1999 and through the date of this filing), which
have been corrected.  The Company will continue to closely monitor its computer
based systems and equipment and other business activities for possible problems
related to Y2K; however, as of the date of this filing, the Company believes its
business operations will not be adversely affected by Y2K.

ACQUISITION

As discussed in Note 7 of the Notes to Consolidated Financial Statements, on
December 16, 1999, the Company and Implant Innovations International Corporation
completed their merger.

PART II.  OTHER INFORMATION

Item 1: Legal Proceedings.

On June 30, 1999, the United States Court of Appeals for the Third Circuit (the
"Third Circuit") significantly reduced the judgment previously entered against
the Company and its wholly-owned subsidiaries, Electro-Biology, Inc. and EBI
Medical Systems, Inc. and in favor of Orthofix SRL ("Orthofix").  The Third
Circuit upheld the trial court's award of compensatory damages to Orthofix in
the amount of $48,875,397; however, it virtually eliminated the $50 million
punitive damage award, reducing it to $1 million.  The Company and Orthofix
filed petitions for rehearing with the Third Circuit and both petitions were
denied.  Orthofix filed an appeal of the Third Circuit's decision to the United
States Supreme Court, and on January 10, 2000 the Supreme Court decided, without
comment, not to review the decision of the lower court.  As a result of the
Third Circuit's decision, and consultation with outside legal counsel, the
Company recorded a special charge of $55 million in its fiscal 1999 consolidated
financial statements.  The Company recorded an additional special charge of $9
million for the quarter ended November 30, 1999 to reflect the final
determination of the interest element of the judgment.  On November 30, 1999,
the Company's investments on the consolidated balance sheet include $108 million
of investment securities which were previously delivered to an escrow agent
pursuant to an order of the trial court.  It is anticipated that the final
amount payable to Orthofix of approximately $64 million will be paid prior to
January 31, 2000, at which time this matter will be finally resolved and the
escrow account closed.

Item 6.  Exhibits and Reports on Form 8-K

     (a)  Exhibits.  See Index to Exhibits.
     (b)  Reports on Form 8-K. 	None.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.


BIOMET, INC.
------------
(Registrant)


DATE:   1/14/2000         BY: /s/  GREGORY D. HARTMAN
       ----------                  -------------------------
                                   Gregory D. Hartman
                                   Senior Vice President - Finance and Treasurer
                                   (Principal Financial Officer)

                                   (Signing on behalf of the Registrant
                                    and as Principal Financial Officer)

BIOMET, INC.

FORM 10-Q

INDEX TO EXHIBITS

                                                               Sequential
Number Assigned                                                Numbering System
in Regulation S-K                                              Page Number
Item 601               Description of Exhibit                  of Exhibit
-----------------      --------------------------------        ----------------
(2)                    No exhibit.

(4)                    4.1 Specimen certificate for Common
                       Shares.  (Incorporated by reference
                       to Exhibit 4.1 to the registrant's
                       Report on Form 10-K for the fiscal
                       year ended May 31, 1985).

                       4.2  Rights Agreement between Biomet,
                       Inc. and Lake City Bank, as Rights
                       Agent, dated as of December 16, 1999.
                       (Incorporated by reference to Exhibit
                       4.01 to Biomet, Inc. Form 8-K Current Report
                       dated December 16, 1999, File No. 0-12515).

(10)                   No exhibit.

(11)                   No exhibit.

(15)                   No exhibit.

(18)                   No exhibit.

(19)                   No exhibit.

(22)                   No exhibit.

(23)                   No exhibit.

(24)                   No exhibit.

(27)                   Financial data schedules.

(99)                   No exhibit.